Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

p>

  • Top line results from the phase II trial in healthy adults with our trivalent seasonal flu vaccine candidate;
  • Preclinical results of studies with vaccine candidates against the Respiratory Syncitial Virus (RSV);
  • Commencement of operations of the joint venture with Cadila Pharmaceuticals Ltd in India; and,
  • Initiation of a Phase II clinical study of our trivalent seasonal flu vaccine in older adults.

2009 Financial Results

Revenue from operations for the first quarter ended March 31, 2009 was $0.02 million compared to $0.5 million for the same period in 2008, a net decrease of $0.4 million due to the completion of a government contract in the first quarter of 2009.

Research and development costs for the first quarter of 2009 were $4.3 million compared to $4.4 million in the first quarter of 2008. The decrease was due to a $0.2 million decrease in employee costs and a $0.1 million decrease associated with the closing of the Taft Court facility in October 2008 when the Company consolidated its operations into the Belward Campus facility. These decreases were partially offset by an increase in $0.1 million in outside testing costs associated with the continuing clinical trials, preclinical testing, process development, manufacturing and quality related programs and a $0.1 million increase in facility costs.

General and administrative costs were $2.9 million in the first quarter of 2009 as compared to $3.2 million in the first quarter of 2008. The $0.3 million decrease was due to a decrease in employee costs of $0.1 million, a decrease in facility costs associated with general and administrative functions of $0.1 million, and a decrease of $0.2 million in charges to the allowance established for two notes receivable from former directors. The Company determined that the notes receivable
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
(Date:10/22/2014)... KONG , Oct. 22, 2014  aTyr Pharma ... that rare disease expert John C. McKew , ... McKew brings more than two decades of expertise in ... Institutes of Health, Wyeth Research and Genetics Institute, Inc. ... aTyr,s efforts to expand and translate its novel Physiocrine ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... 19 , - Shocking Lack of Global Statistics ... Atlas, The World Hepatitis Alliance, a newly formed ... do more to,drive improvements in prevention, diagnosis and treatment ... Although it is estimated that 500 million, approximately ...
... Biosystems,Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art,gene ... the signing of two separate private placements. The details,of the ... -- WaferGen has agreed to sell shares of the ... certain funds for which Brencourt Advisors is the ...
... YORK, May 19 Intellect Neurosciences,Inc. (OTC ... on,development of disease-modifying therapeutic agents for the ... today that it has entered,into a license ... and Elan Pharma,International Ltd. ("Elan") regarding certain ...
Cached Biology Technology:World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic 2World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic 3WaferGen Announces Signing of Two Private Placements 2WaferGen Announces Signing of Two Private Placements 3WaferGen Announces Signing of Two Private Placements 4WaferGen Announces Signing of Two Private Placements 5Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd. 2Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd. 3
(Date:10/15/2014)... from strains of influenza virus increases with the latest ... complacent that the most substantial threats have been identified, ... arise when a new virus strain – against which ... in the human population. There have been five such ... which – the 1918 Spanish Flu – cost 50 ...
(Date:10/15/2014)... virus is spreading rapidly and to an unexpected extent. ... the past and the virus shows a new disease ... before. For this reason, the German National Academy of ... and Engineering, and the Union of the German Academies ... the Ebola epidemic today. , In the statement the ...
(Date:10/15/2014)... Geneticist Fred Alt will be awarded the 44th Rosenstiel ... University for his pioneering research exploring the mechanisms of ... and cancer cells. Alt is the second alumnus to ... the Nobel Prize in 2003. , Alt is the ... Genetics at Harvard Medical School and an investigator at ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... today a $480,000 gift from the Emily Landecker Foundation. ... in Astrobiology, which will support graduate students in the ... of astrobiology. The fellowship is named in honor of ... currently a senior research professor, and a member of ...
... yuck factor, have captured the hearts of two University of ... this week is publishing the leech,s complete genome sequence. ... UC Berkeley professor of molecular and cell biology who lobbied ... that has targeted a variety of animals in order to ...
... Medical Center researchers have pinpointed a molecular mechanism needed ... step toward developing eventual therapies for damage suffered following ... UT Southwestern, teaming up to study in mice how ... that regulate gene expression contribute to the heart,s ...
Cached Biology News:Rensselaer awarded gift to establish fellowship in astrobiology 2What do leeches, limpets and worms have in common? Now, a sequenced genome 2What do leeches, limpets and worms have in common? Now, a sequenced genome 3Research pinpoints key gene for regenerating cells after heart attack 2
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
... Microarray Gene Frame® has been specifically ... frames feature the same dual strength ... Frame® range for easy removal after ... and there are three sizes available. ...
For microscopy...
... slide processing offering reproducibility, reliability and ... miniaturization, automation and massive parallel analysis ... with many applications in both industrial ... from gene expression profiling, gene regulation ...
Biology Products: